Imaging standards in the national breast screening programme

1996 ◽  
Author(s):  
M.E. Hanson
Keyword(s):  
Breast Screening ◽  
Screening Programme ◽  
Breast Screening Programme ◽  
National Breast

Evolution of the National Breast Screening Programme in Ireland: Two-year interval analysis (2004–2013) of BreastCheck

2017 ◽  
Vol 25 (4) ◽  
pp. 191-196 ◽  
Author(s):  
Patricia E Fitzpatrick ◽  
Gráinne Greehy ◽  
Marie T Mooney ◽  
Fidelma Flanagan ◽  
Aideen Larke ◽  
...  
Keyword(s):  
Cancer Detection ◽  
Digital Mammography ◽  
Carcinoma In Situ ◽  
Breast Screening ◽  
Screening Programme ◽  
Ductal Carcinoma ◽  
Detection Rates ◽  
Breast Screening Programme ◽  
National Breast

Objective Monitoring breast screening programmes is essential to ensure quality. BreastCheck, the national breast screening programme in the Republic of Ireland, commenced screening in 2000, with full national expansion in 2007, and digital mammography introduced in 2008. We aimed to review the performance of BreastCheck from 1 January 2004 to 31 December 2013. Methods Using the customised clinical and administrative database, performance indicator data were collected from BreastCheck and compared with programme and European guideline standards. Results Over the decade, 972,236 screening examinations were performed. Uptake initially rose following national expansion, but fell in the subsequent years to <70% in 2012–2013. Following the introduction of digital mammography, initial recall rates increased from 5.2% in 2004–2005 to 8.1% in 2012–2013. Subsequent recall rates remained within the target of <3%. On average, invasive cancer detection rates were 6.6/1000 for initial and 4.5/1000 for subsequent women. Small cancer detection rates were for <15 mm 43.4% (initial women) and 51.7% (subsequent) and for ≤10 mm 24.0% (initial) and 29.5% (subsequent). Ductal carcinoma in situ detection as a percentage of all cancers averaged 21.2% for initial and 20.0% for subsequent women. The majority were intermediate or high-grade ductal carcinoma in situ. The positive predictive value was 11.9% for initial and 21.8% for subsequent women. Standardized detection ratios remained above the programme target. Conclusion Revised indicators to reflect the digital mammography era are anticipated in revised European Guidelines on breast cancer screening.

Organisational readiness for the adoption of AI diagnostic tools in clinical workflows – a case study from the National Breast Screening Programme in the East Midlands of England. (Preprint)

2020 ◽  
Author(s):  
Niamh Lennox-Chhugani ◽  
Simon Harris ◽  
Jacqueline Moxon ◽  
Vipul Patel
Keyword(s):  
Real World ◽  
Breast Screening ◽  
Screening Programme ◽  
Decision Makers ◽  
Diagnostic Tools ◽  
Healthcare Organisation ◽  
Breast Screening Programme ◽  
The Real ◽  
National Breast

BACKGROUND Application of artificial intelligence (AI) in healthcare is accelerating but relatively little is yet known about the real-world implementation of AI in clinical workflows. OBJECTIVE In this paper, we have focused on one application of AI as a second reader of breast mammograms in the context of a national breast screening programme. We look at the development and testing of an AI image reading tool for mammograms and the effect of organisational readiness for AI tool adoption. We focus on two aspects of organisational readiness as conceptualised by Weiner (2009) for AI technology specifically and answer the questions (1) what are the views of the technology adopters in a healthcare organisation to the use of AI technology in the case of breast screening? (2) What are some of the emerging organisation factors that are likely to effect adoption and spread and are any unique to AI technology? METHODS A prospective mixed methods study of the real-world development of AI tools for use in the National Breast Screening Programme in England. We recruited 67 radiologists and reporting radiographers in four breast screening services and 18 organisational leaders who were the AI project decision-makers. Data was collected using an online survey of breast screening staff (adopters), semi-structured interviews with organisational leaders, participant observation of project meetings and document review. Data regarding organisational and adopter readiness for technology adoption was analysed over the duration of the project. RESULTS Sixty-seven clinicians and eighteen organisational leaders participated the study. Commitment to adoption is positive but adopters want to see clinical evidence of AI safety and accuracy. Decision-makers and other organisational adopters do not yet have shared views on their resources, capacity and capability to adopt and spread the technology and significant challenges related to task demands and situational factors emerged during the project causing substantial delays to adoption. The nature of AI and ML technology surfaced novel complexities not encountered by traditional health technology related to explainability and meaningful decision-support. CONCLUSIONS The case study shows that adopter commitment in this case and AI technology in breast screening is growing but gaps remain in the collective capability of organisations to adopt these novel technologies. CLINICALTRIAL Not applicable

Sign in / Sign up

Export Citation Format

Share Document